☰

Hank Michael Petrassi - Publications

Affiliations: 
2001 Scripps Research Institute, La Jolla, La Jolla, CA, United States 
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Liu YA, Jin Q, Zou Y, Ding Q, Yan S, Wang Z, Hao X, Nguyen B, Zhang X, Pan J, Mo T, Jacobsen K, Lam T, Wu TY, Petrassi HM, et al. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. Journal of Medicinal Chemistry. PMID 32077280 DOI: 10.1021/Acs.Jmedchem.9B01624  0.581
2019 Bakowski MA, Shiroodi RK, Liu R, Olejniczak J, Yang B, Gagaring K, Guo H, White PM, Chappell L, Debec A, Landmann F, Dubben B, Lenz F, Struever D, Ehrens A, ... ... Petrassi HM, et al. Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections. Science Translational Medicine. 11. PMID 31068442 DOI: 10.1126/Scitranslmed.Aav3523  0.71
2018 Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, Love MS, Hull MV, Kuhen KL, Woods AK, Joseph SB, Petrassi HM, McNamara CW, Tremblay MS, Su AI, et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America. 115: 10750-10755. PMID 30282735 DOI: 10.1073/Pnas.1810137115  0.677
2017 Choi SH, Mahankali M, Lee SJ, Hull M, Petrassi HM, Chatterjee AK, Schultz PG, Jones KA, Shen W. Targeted disruption of Myc-Max oncoprotein complex by a small molecule. Acs Chemical Biology. PMID 28976731 DOI: 10.1021/Acschembio.7B00799  0.574
2005 Petrassi HM, Johnson SM, Purkey HE, Chiang KP, Walkup T, Jiang X, Powers ET, Kelly JW. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. Journal of the American Chemical Society. 127: 6662-71. PMID 15869287 DOI: 10.1021/Ja044351F  0.749
2005 Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, Kelly JW. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. Journal of Medicinal Chemistry. 48: 1576-87. PMID 15743199 DOI: 10.1021/Jm049274D  0.747
2002 McCammon MG, Scott DJ, Keetch CA, Greene LH, Purkey HE, Petrassi HM, Kelly JW, Robinson CV. Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure (London, England : 1993). 10: 851-63. PMID 12057199 DOI: 10.1016/S0969-2126(02)00771-2  0.714
2002 Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, Chiang KP, Powers ET, Sachettinni J, Kelly JW. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. Journal of Medicinal Chemistry. 45: 321-32. PMID 11784137 DOI: 10.1021/Jm010257N  0.734
2001 Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, Kelly JW. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry. 40: 11442-52. PMID 11560492 DOI: 10.1021/Bi011194D  0.694
2001 Petrassi HM, Sharpless KB, Kelly JW. The copper-mediated cross-coupling of phenylboronic acids and N-hydroxyphthalimide at room temperature: synthesis of aryloxyamines. Organic Letters. 3: 139-42. PMID 11429858 DOI: 10.1021/Ol0003533  0.372
2000 Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nature Structural Biology. 7: 312-21. PMID 10742177 DOI: 10.1038/74082  0.537
2000 Kelly JW, Petrassi HM, Oza V, Purkey H, Koepf E, Raman P, Klabunde T, Sacchettini J. Structure-Based Design, Synthesis and Evaluation of Amyloid Fibril Inhibitors Biochemical Society Transactions. 28: A51-A51. DOI: 10.1042/Bst028A051  0.697
2000 Petrassi HM, Klabunde T, Sacchettini J, Kelly JW. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors Journal of the American Chemical Society. 122: 2178-2192. DOI: 10.1021/Ja993309V  0.561
1999 Koepf EK, Petrassi HM, Ratnaswamy G, Huff ME, Sudol M, Kelly JW. Characterization of the structure and function of W --> F WW domain variants: identification of a natively unfolded protein that folds upon ligand binding. Biochemistry. 38: 14338-51. PMID 10572009 DOI: 10.1021/bi991105l  0.707
1999 Koepf EK, Petrassi HM, Sudol M, Kelly JW. WW: An isolated three-stranded antiparallel beta-sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state. Protein Science : a Publication of the Protein Society. 8: 841-53. PMID 10211830 DOI: 10.1110/Ps.8.4.841  0.425
1999 Oza VB, Petrassi HM, Purkey HE, Kelly JW. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorganic & Medicinal Chemistry Letters. 9: 1-6. PMID 9990446 DOI: 10.1016/S0960-894X(98)00696-9  0.71
Show low-probability matches.